Drugmakers Slash Prices to Be Eligible for China’s Bulk-Buy Program
Beijing has been pushing forward the program where drugmakers have to go through a bidding process and cut prices low enough to be considered over generic copies and be allowed to sell their products at public hospitals via large-volume government procurement. Some global firms such as AstraZeneca and Merck have already cautioned about …
News story posted on 2020-01-18T08:47:00.0000000Z
